| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rociletinib in EGFR-mutated non-small-cell lung cancer.
|
N Engl J Med
|
2015
|
6.28
|
|
2
|
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
|
J Clin Oncol
|
2011
|
3.73
|
|
3
|
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2005
|
1.79
|
|
4
|
Metabolic tumor burden predicts for disease progression and death in lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.69
|
|
5
|
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
|
BioDrugs
|
2009
|
1.22
|
|
6
|
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.
|
Lab Chip
|
2014
|
1.07
|
|
7
|
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
|
J Thorac Oncol
|
2012
|
1.05
|
|
8
|
Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
|
J Thorac Oncol
|
2015
|
1.02
|
|
9
|
Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
|
Curr Opin Investig Drugs
|
2009
|
0.98
|
|
10
|
How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox.
|
J Clin Oncol
|
2013
|
0.97
|
|
11
|
Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.
|
J Thorac Oncol
|
2009
|
0.96
|
|
12
|
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
|
Lung Cancer
|
2012
|
0.95
|
|
13
|
Adjuvant treatment of resected lung cancer.
|
Proc Am Thorac Soc
|
2009
|
0.93
|
|
14
|
Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.93
|
|
15
|
Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
0.91
|
|
16
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
17
|
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
|
Clin Lung Cancer
|
2013
|
0.90
|
|
18
|
Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.89
|
|
19
|
Current management of small cell lung cancer.
|
Clin Chest Med
|
2011
|
0.85
|
|
20
|
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
|
Clin Adv Hematol Oncol
|
2012
|
0.85
|
|
21
|
Sex differences in lung-cancer susceptibility: a smoke screen?
|
Lancet Oncol
|
2008
|
0.85
|
|
22
|
Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response.
|
Clin Lung Cancer
|
2006
|
0.84
|
|
23
|
Lung cancer presenting with amegakaryocytic thrombocytopenia.
|
J Clin Oncol
|
2008
|
0.84
|
|
24
|
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
|
Lung Cancer
|
2012
|
0.80
|
|
25
|
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.80
|
|
26
|
Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.80
|
|
27
|
MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.
|
J Thorac Oncol
|
2015
|
0.79
|
|
28
|
Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
|
Cancer Invest
|
2012
|
0.78
|
|
29
|
Adjuvant chemotherapy for early stage non-small cell lung cancer.
|
Front Oncol
|
2011
|
0.78
|
|
30
|
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
|
Nat Commun
|
2016
|
0.77
|
|
31
|
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.76
|
|
32
|
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
|
Anticancer Drugs
|
2013
|
0.76
|
|
33
|
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
|
J Thorac Oncol
|
2008
|
0.76
|
|
34
|
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.
|
J Natl Compr Canc Netw
|
2013
|
0.76
|
|
35
|
Pruritus as a Paraneoplastic Symptom of Thymoma.
|
J Thorac Oncol
|
2015
|
0.75
|
|
36
|
A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
|
J Thorac Oncol
|
2013
|
0.75
|
|
37
|
Response.
|
Chest
|
2013
|
0.75
|
|
38
|
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
|
Immunopharmacol Immunotoxicol
|
2014
|
0.75
|
|
39
|
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
|
Cancer Chemother Pharmacol
|
2011
|
0.75
|
|
40
|
Aflibercept in lung cancer.
|
Expert Opin Biol Ther
|
2012
|
0.75
|
|
41
|
A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma.
|
Clin Lung Cancer
|
2006
|
0.75
|